News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Long-term survival with glioblastoma multiforme.

Posted on: 09/09/2007

Brain. 2007 Sep 4; [Epub ahead of print] Related Articles

Long-term survival with glioblastoma multiforme.

Krex D, Klink B, Hartmann C, Deimling AV, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G; for the German Glioma Network.

Department of Neurosurgery, Carl Gustav Carus University Hospital, University of Technology, Dresden, Department of Neuropathology, Heinrich -Heine University, Dusseldorf, Department of Neuropathology, Charite-University Medicine Berlin, Department of Neuropathology, Ruprecht-Karls-University, Heidelberg, Department of Neuropathology, and Department of Neurosurgery, University of Bonn Medical Centre, Bonn, Department of Neurosurgery, Heinrich-Heine University Dusseldorf, Department of General Neurology, Hertie Institute for Clinical Brain Research, T ubingen and Department of Neurological Surgery, University Medical Centre Hamburg-Eppendorf, Germany.

The median survival of glioblastoma patients is approximately 12 months. However, 3-5% of the patients survives for more than 3 years and are referred to as long-term survivors. The clinical and molecular factors that contribute to long-term survival are still unknown. To identify specific parameters that might be associated with this phenomenon, we performed a detailed clinical and molecular analysis of 55 primary glioblastoma long-term survivors recruited at the six clinical centres of the German Glioma Network and one associated centre. An evaluation form was developed and used to document demographic, clinical and treatment-associated parameters. In addition, environmental risk factors, associated diseases and occupational risks were assessed. These patients were characterized by young age at diagnosis and a good initial Karnofsky performance score (KPS). None of the evaluated socioeconomic, environmental and occupational factors were associated with long-term survival. Molecular analyses revealed MGMT hypermethylation in 28 of 36 tumours (74%) investigated. TP53 mutations were found in 9 of 31 tumours (29%) and EGFR amplification in 10 of 38 tumours (26%). Only 2 of 32 tumours (6%) carried combined 1p and 19q deletions. Comparison of these data with results from an independent series of 141 consecutive unselected glioblastoma patients registered in the German Glioma Network revealed significantly more frequent MGMT hypermethylation in the long-term survivor group. Taken together, our findings underline the association of glioblastoma long-term survival with prognostically favourable clinical factors, in particular young age and good initial performance score, as well as MGMT promoter hypermethylation.

PMID: 17785346 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557